JanOne (Nasdaq: JAN), a US-based biopharmaceutical company, announced on Thursday that it has named John N Bonfiglio, PhD, as interim president of its JanOne Biotech subsidiary.
Dr Bonfiglio has served at Allergan Pharmaceuticals and Baxter HealthCare and then turned to discovering, promoting and leading smaller biotech ventures. He has served as CEO at Peregrine Pharmaceuticals. He has over 30 years of experience, with achievements including helping Cypress Bioscience reinvent itself as a neuro-pharmaceutical company and, as CEO of Immune Response Corporation, raising over USD50m and restarting clinical trials in HIV and MS. Presently, he is a board member for Avipero and executive board member for Sequella.
Tony Isaac, JanOne's CEO, said, 'We are delighted and honoured to have Dr Bonfiglio join us. His experience in running public biotech companies will prove invaluable to the progress of JanOne. Our entire team looks forward to working with him.'
genedrive secures initial overseas orders for Genedrive MT-RNR1 ID kit
Kromek collaborates on next-gen CT detector technology
Gilead Sciences initiates Phase 2 trial in Europe to evaluate lenacapavir for HIV prevention
European Commission grants authorisation to ViiV Healthcare's Apretude for prevention of HIV
Celanese to supply VitalDose drug delivery platform for Population Council's MPT Intravaginal Ring
Henry Schein introduces equipment repair subscription - Henry Schein Thrive Service Plus
Seres Therapeutics provides business updates and reports Q2 2023 financial results